JP2018501797A - 炎症性大腸疾患の診断、モニタリング、および処置のためのプロバイオティック生物 - Google Patents

炎症性大腸疾患の診断、モニタリング、および処置のためのプロバイオティック生物 Download PDF

Info

Publication number
JP2018501797A
JP2018501797A JP2017534611A JP2017534611A JP2018501797A JP 2018501797 A JP2018501797 A JP 2018501797A JP 2017534611 A JP2017534611 A JP 2017534611A JP 2017534611 A JP2017534611 A JP 2017534611A JP 2018501797 A JP2018501797 A JP 2018501797A
Authority
JP
Japan
Prior art keywords
promoter
cell
recombinant
molecule
output
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017534611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501797A5 (https=
Inventor
ルー，ティモシー，クァン−タ
ルーベンス，ジェイコブ，ローゼンブルーム
ミュラー，アイザック，エリス
セルヴァッジョ，ジャンルカ
ミラー，ポール
ファルブ，ディーン
イザベラ，ヴィンセント
コートゥラ，ジョナサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synlogic Inc
Original Assignee
Synlogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synlogic Inc filed Critical Synlogic Inc
Publication of JP2018501797A publication Critical patent/JP2018501797A/ja
Publication of JP2018501797A5 publication Critical patent/JP2018501797A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
JP2017534611A 2014-12-22 2015-12-22 炎症性大腸疾患の診断、モニタリング、および処置のためのプロバイオティック生物 Pending JP2018501797A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095415P 2014-12-22 2014-12-22
US62/095,415 2014-12-22
PCT/US2015/067435 WO2016106343A1 (en) 2014-12-22 2015-12-22 Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
JP2018501797A true JP2018501797A (ja) 2018-01-25
JP2018501797A5 JP2018501797A5 (https=) 2019-02-07

Family

ID=55273522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017534611A Pending JP2018501797A (ja) 2014-12-22 2015-12-22 炎症性大腸疾患の診断、モニタリング、および処置のためのプロバイオティック生物

Country Status (6)

Country Link
US (1) US20170360850A1 (https=)
EP (1) EP3237437A1 (https=)
JP (1) JP2018501797A (https=)
AU (1) AU2015369627A1 (https=)
CA (1) CA2971876A1 (https=)
WO (1) WO2016106343A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
EP3622093A4 (en) * 2017-05-12 2021-05-26 Baylor College of Medicine DEVELOPMENT OF MICROBIAL BIOSENSORS FOR INTESTINAL IGNITION
WO2019047166A1 (en) 2017-09-08 2019-03-14 New Portal Limited NUCLEIC ACID SYSTEMS THAT ALLOW BACTERIA TO SPECIFICALLY TARGET SOLID TUMORS THROUGH GLUCOSE DEPENDENT VIABILITY
WO2019203802A1 (en) 2018-04-17 2019-10-24 Massachusetts Institute Of Technology An ingestible system to monitor gastrointestinal health in situ
JP2022512639A (ja) * 2018-10-09 2022-02-07 セカンド ゲノム インコーポレイテッド 上皮バリア機能障害の治療に有効なタンパク質を送達するためのラクトコッカス・ラクティス発現系
US11926849B2 (en) 2019-03-29 2024-03-12 The General Hospital Corporation Biosensors in human gut organoids
CA3142608A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
WO2021048172A2 (en) 2019-09-09 2021-03-18 River Stone Biotech Aps Delivery vehicle for in situ delivering of pharmaceutical agents
WO2022006748A1 (en) 2020-07-07 2022-01-13 New Portal Limited Genetically engineered live bacteria and methods of constructing the same
CN112961872B (zh) * 2021-02-25 2022-09-30 上海健康医学院 益生菌嵌合传感器及其构建方法和应用
EP4508236A4 (en) * 2022-04-13 2026-04-15 Baylor College Medicine Bacterial biosensors for the diagnosis and treatment of inflammation
WO2025233942A1 (en) * 2024-05-07 2025-11-13 Technion Research & Development Foundation Limited Synthetic microbiome consortia and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527988A (ja) * 2005-01-25 2008-07-31 ユニヴァーシティ・オヴ・リーズ 腸内細菌による生物活性物質の制御された産生および送達

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105144204B (zh) * 2012-12-13 2018-02-27 麻省理工学院 基于重组酶的逻辑与存储系统

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527988A (ja) * 2005-01-25 2008-07-31 ユニヴァーシティ・オヴ・リーズ 腸内細菌による生物活性物質の制御された産生および送達

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACS SYNTHETIC BIOLOGY, vol. 1, no. 10, JPN5017011071, 2012, pages 451 - 457, ISSN: 0004350175 *
J. PHYSIOL. PHARMACOL., vol. Vol. 60, Suppl. 6, JPN6020001480, 2009, pages 49 - 54, ISSN: 0004350176 *
京府医大誌, vol. 123, no. 4, JPN6020001481, March 2014 (2014-03-01), pages 233 - 245, ISSN: 0004350177 *

Also Published As

Publication number Publication date
US20170360850A1 (en) 2017-12-21
WO2016106343A1 (en) 2016-06-30
CA2971876A1 (en) 2016-06-30
EP3237437A1 (en) 2017-11-01
AU2015369627A1 (en) 2017-07-06
WO2016106343A8 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
JP2018501797A (ja) 炎症性大腸疾患の診断、モニタリング、および処置のためのプロバイオティック生物
Lim et al. Engineered regulatory systems modulate gene expression of human commensals in the gut
RU2757933C2 (ru) Новые генно-инженерные вирусы осповакцины
Denou et al. Identification of genes associated with the long-gut-persistence phenotype of the probiotic Lactobacillus johnsonii strain NCC533 using a combination of genomics and transcriptome analysis
DK2714912T3 (en) POLYCISTRONIC EXPRESSION SYSTEM FOR BACTERIA
KR20170121291A (ko) 감소된 창자 염증 및/또는 강화된 창자 점막 장벽으로부터 이익을 얻는 질병을 치료하기 위해 공학처리된 박테리아
Özçam et al. Gut symbionts Lactobacillus reuteri R2lc and 2010 encode a polyketide synthase cluster that activates the mammalian aryl hydrocarbon receptor
Zuo et al. Inducible plasmid self-destruction (IPSD) assisted genome engineering in lactobacilli and bifidobacteria
Effendi et al. Prospective and challenges of live bacterial therapeutics from a superhero Escherichia coli Nissle 1917
Chen et al. Decoding the microbiome: advances in genetic manipulation for gut bacteria
Gao et al. GidA, a tRNA modification enzyme, contributes to the growth, and virulence of Streptococcus suis serotype 2
US20210115455A1 (en) Compositions and methods for regulated gene expression
Lucchini et al. The role of OmpR in bile tolerance and pathogenesis of adherent-invasive Escherichia coli
Krishnan et al. Pili in probiotic bacteria
Shkoporov et al. Production of human basic fibroblast growth factor (FGF-2) in Bifidobacterium breve using a series of novel expression/secretion vectors
Gopal et al. C-terminal domain of CagX is responsible for its interaction with CagT protein of Helicobacter pylori type IV secretion system
Kim et al. Novel signal peptides and episomal plasmid system for enhanced protein secretion in engineered Bacteroides species
EP3802788B1 (en) Systems and methods for genetic manipulation of akkermansia species
CN115701771A (zh) 胆盐细菌传感器及其在诊断和治疗中的用途
CN115916981B (zh) 治疗癌症的沙门氏菌株及其应用
Dacquay Genetically Engineering Microbes for Detecting and Treating Inflammatory Bowel Disease
Cohen et al. A tetRA-based promoter system for the generation of conditional knockouts in Campylobacter jejuni
Kurt Engineering of Probiotic Saccharomyces boulardii as a Host for Living Therapeutic Applications
AU2024201593B2 (en) A genetically modified Lactobacillus and uses thereof
WO2024064888A2 (en) Engineered microorganisms with enhanced protein expression and secretion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200421

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200923